Latest Biomaterials News

Page 1 of 3
Nanollose has narrowed its microbial cellulose scale-up plan to one company-controlled Western Australian pilot facility, with all Stage 1 equipment ordered and paid for. The progress comes with a clear funding constraint: the ASX-listed biomaterials developer ended September with $758,000 in cash, equivalent to 1.41 quarters of funding at its current operating burn.
Victor Sage
Victor Sage
30 Oct 2026
ReNerve Ltd (ASX:RNV) reported an 80% year-on-year revenue increase in Q4 FY26, backed by expanding product lines and a $5 million funding facility. The company is advancing FDA approvals and growing its global distribution footprint, targeting a rapidly expanding $6.19 billion nerve repair biomaterials market.
Ada Torres
Ada Torres
19 Aug 2026
ReNerve has appointed J4 Biologics as a second manufacturer for its Empliq range to meet growing hospital approvals and market demand, strengthening its supply chain and scaling production capacity.
Ada Torres
Ada Torres
11 June 2026
ReNerve Limited has appointed UG Medical to distribute its NervAlign nerve repair products in Malaysia, tapping into a fast-growing healthcare market backed by government investment.
Ada Torres
Ada Torres
5 June 2026
Vitrafy Life Sciences has teamed up with Vitalant Innovation Center to tackle the impending gap in red blood cell cryopreservation technology in the US, aiming to replace soon-to-be-discontinued legacy methods and potentially expand into other blood products.
Ada Torres
Ada Torres
2 June 2026
Tetratherix Limited secures $15 million via institutional placement plus a capped $2 million share purchase plan at a 14% discount, aiming to fast-track manufacturing expansion and commercial partnerships.
Ada Torres
Ada Torres
28 May 2026
Vitrafy Life Sciences has achieved a major validation milestone with US Army-backed Phase II results showing its no-wash platelet cryopreservation protocol delivers 94% post-thaw recovery, outperforming existing standards and advancing FDA registration plans.
Ada Torres
Ada Torres
22 May 2026
Tetratherix Limited reported a $4.6 million statutory loss for the first half of FY26, driven by increased R&D and manufacturing investments, while making significant progress in clinical trials and securing key global partnerships.
Ada Torres
Ada Torres
24 Feb 2026
Nanollose has advanced its largest pilot production of Nullarbor™ fibre, integrating a refined microbial cellulose process that promises easier adoption by textile manufacturers. The company also bolstered its intellectual property portfolio and secured additional funding post-quarter.
Maxwell Dee
Maxwell Dee
30 Jan 2026
Tetratherix Limited (ASX, TTX) reports significant progress in clinical trials, strategic partnerships, and manufacturing capacity, positioning itself for near-term commercialisation and sustained innovation.
Ada Torres
Ada Torres
28 Jan 2026
Osteopore Limited has secured an exclusive multi-year distribution agreement with Majeton to commercialise its dental and maxillofacial products in China, Hong Kong, and Macau, marking a major step in its Asia-Pacific expansion.
Ada Torres
Ada Torres
16 Jan 2026
ReNerve Limited has secured broader regulatory approval in Hong Kong for its NervAlign® Nerve Cuff, enabling access to both public and private hospitals and validating the device’s clinical benefits through independent review.
Ada Torres
Ada Torres
12 Jan 2026

Browse the archive

Full archive